Artios Adds $153M to the Bank Amidst a Year of Major Collab Deals

In the past year, Artios Pharma has snagged some big-name partnerships for its candidates. This week's $153 million Series C raise adds to the funding pipeline.

The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers. One hallmark of cancer cells is the down-regulation or loss of certain DDR pathways. Artios' inhibitors work by exploiting cancer cells with defective DDR either as a monotherapy or in combination with other approaches.